Background/Aims: Visfatin is an adipocytokine predominantly expressed in visceral adipose tissue. We examined the relationship between plasma visfatin concentrations and anthropometric and metabolic parameters in children and adolescents, who are relatively less influenced by the effects of accompanying disease. Methods: We studied 135 children and adolescents (8-16 years old). Plasma glucose, insulin, lipid profile, visfatin and other adipocytokine levels were measured. CT scans were performed to evaluate the distribution of abdominal fat. We analyzed the relationship between circulating visfatin levels and anthropometric and metabolic parameters according to central adiposity (total abdominal fat by CT scan). Results: In the lower-adiposity group, plasma visfatin concentrations were significantly correlated with total abdominal fat, visceral fat, subcutaneous abdominal fat, plasma triglyceride level and homeostasis model assessment of insulin resistance (HOMA-IR). In a multiple linear regression analysis, visceral fat and triglycerides were independently associated with plasma visfatin levels. In the higher-adiposity group, plasma visfatin concentrations were not correlated with visceral fat or HOMA-IR but were significantly correlated with circulating interleukin-6 levels. Conclusion: These data suggest that the relationship between plasma visfatin concentrations and metabolic parameters differs according to central adiposity and that plasma visfatin concentrations are correlated with visceral fat and triglyceride levels, especially in children and adolescents with lower adiposity.

1.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430, withdrawn.
2.
Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-1437.
3.
Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F: Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002;32:3225-3234.
4.
Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B: Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Matab 2006;91:1578-1581.
5.
Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, Semik-Grabarczyk E, Holecki M, Dabrowski P, Skorupa A: Serum concentration of visfatin in obese women. Metabolism 2007;56:1131-1134.
6.
García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, Gallego-Perales JL, Rojo-Martínez G, Garrido-Sánchez L, Bermudez-Silva FJ, Rodríguez de Fonseca F, Soriguer F: Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity 2007;15:2391-2395.
7.
Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R: Reduced plasma visfatin/pre-B cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-3170.
8.
Ingelsson E, Larson MG, Fox CS, Yin X, Wang TJ, Lipinska I, Pou KM, Hoffmann U, Benjamin EJ, Keaney JF Jr, Vasan RS: Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007;30:1278-1280.
9.
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ: Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-299.
10.
Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, Park JW, Song ES, Vu V, Kim W, Tungtrongchitr R, Havel PJ, Swarbrick MM, Shaw C, Sweeney G: Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008;69:885-893.
11.
El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI: Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011;60:63-70.
12.
Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ: Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515-527.
13.
Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A: Visfatin in juvenile obesity - the effect of obesity intervention and sex. Eur J Clin Invest 2011;41:1284-1291.
14.
Oki K, Yamane K, Kamei N, Nojima H, Kohno N: Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007;67:796-800.
15.
Kang YS, Song HK, Lee MH, Ko GJ, Cha DR: Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract 2010;89:141-149.
16.
Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC: Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318-1327.
17.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758.
18.
Seo JA, Jang ES, Kim BG, Ryu OH, Kim HY, Lee KW, Kim SG, Choi KM, Baik SH, Choi DS, Kim NH: Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 2008;79:108-111.
19.
Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y, Asayama K, Shirahata A: Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity 2008;16:384-388.
20.
Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, Pfister M, Siest G, Visvikis-Siest S: Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009;32:e71.
21.
Martos-Moreno GÁ, Kratzsch J, Körner A, Barrios V, Hawkins F, Kiess W, Argente J: Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes (Lond) 2011;35:1355-1362.
22.
Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W, Körner A: Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011;54:1200-1211.
23.
Choi YJ, Jo YE, Kim YK, Ahn SM, Jung SH, Kim HJ, Chung YS, Lee KW, Kim DJ: High plasma concentration of remnant lipoprotein cholesterol in obese children and adolescents. Diabetes Care 2006;29:2305-2310.
24.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifugation. Clin Chem 1972;18:499-502.
25.
Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS: Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008;38:71-72.
26.
Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W: Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008;69:878-884.
27.
Liu SW, Qiao SB, Yuan JS, Liu DQ: Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009;71:202-207.
28.
Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, Chiu CA, Chung FM, Shin SJ, Lee YJ: Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009;18:354-359.
29.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
30.
Bouloumié A, Curat CA, Sengenès C, Lolmède K, Miranville A, Busse R: Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005;8:347-354.
31.
Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, Bouloumié A: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-747.
32.
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M: Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005;289:E586-E590.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.